A specific pattern of chromosomal gains and losses in cell-free DNA could help differentiate maternal cancers from benign conditions flagged by prenatal tests. This finding offers a promising diagnostic tool for pregnant individuals with ambiguous test results, potentially reducing reliance on ...

At the Annual Meeting of the Society of Urologic Oncology, Protara Therapeutics announced that TARA-002 showed high response rates in patients with non–muscle invasive bladder cancer who do not respond to, or have not been treated with, Bacillus Calmette-Guerin therapy, which is part of the ...